Bio Medica Laboratories Limited is a pharmaceutical manufacturing company engaged in the production of formulations and healthcare products. The company earns revenue mainly through manufacturing and supplying pharmaceutical products, including injectables, tablets, capsules, dry syrups, ointments, and OTC products for domestic and export markets. Its products are used by hospitals, healthcare institutions, pharmacies, and pharmaceutical companies. The company also focuses on contract manufacturing and formulation development for third-party clients.

Key Clients and Manufacturing Facilities

The company operates manufacturing facilities at Sanwer Road Industrial Area, Indore, Madhya Pradesh. Manufacturing Unit-II is located at Plot No. 11-C, Sector-E, while Manufacturing Unit-I is situated at 254, Sector-F, Indore. These facilities support production of pharmaceutical formulations and healthcare products. The company also has infrastructure for future expansion at Plot No. 11B-11C. Bio Medica works with pharmaceutical distributors, institutional buyers, and healthcare companies across India.

Product Portfolio and Order Book Execution

Bio Medica’s product portfolio includes injectables, tablets, capsules, syrups, ointments, and OTC healthcare products. These products support different stages of the pharmaceutical product life cycle, from acute treatments to chronic therapies. The company also participates in contract manufacturing and formulation services, helping clients reduce production costs and improve speed-to-market. Execution of orders depends on manufacturing capacity, regulatory approvals, quality compliance, and timely raw material procurement.

Expansion Plans, Capex and Future Execution

The company is planning business expansion through the development of a new manufacturing facility at Plot No. 11B-11C, Sector-E, Sanwer Road, Indore. The company has already applied for approvals with MPIDC and Nagar Nigam, Indore. A portion of the IPO proceeds, including around ₹650 lakh, will be used for repayment of borrowings, strengthening the balance sheet, and supporting future capex plans. The expansion is expected to improve production capabilities and operational efficiency.

Employees and Banker to the Company

As of April 30, 2026, the company had 56 full time employees. The Banker to the Company is Kotak Mahindra Bank.

Management and Growth Vision

Bio Medica Laboratories is promoted by Pradeep Mehta and Mukesh Mehta, who together have more than 18-19 years of experience in the pharmaceutical industry. Pradeep Mehta, Managing Director, is responsible for growth strategy, innovation, and overall operations, while Mukesh Mehta handles marketing, business development, and sales operations.

The management is focused on expanding manufacturing capacity, improving product quality standards, and increasing its presence in domestic and export pharmaceutical markets. The company aims to strengthen its position in pharmaceutical formulations, contract manufacturing, and OTC healthcare products.

The long-term growth strategy includes setting up additional manufacturing infrastructure, increasing production automation, and expanding customer relationships with pharmaceutical companies. The management is also focusing on improving regulatory compliance and operational efficiency.

To fund future expansion and capex plans, the company plans to use IPO proceeds, internal accruals, and bank borrowings. Reduction of debt through IPO proceeds is expected to improve the company’s financial flexibility and support future growth opportunities.

Industry Overview

Bio Medica Laboratories operates in the Indian pharmaceutical formulations and contract manufacturing industry. India is one of the world’s largest suppliers of generic medicines and pharmaceutical products. The pharmaceutical sector benefits from increasing healthcare spending, rising chronic diseases, growing export opportunities, and government healthcare initiatives.

India is globally recognized as a major supplier of generic medicines and vaccines. The pharmaceutical industry is expected to continue growing due to rising domestic demand, ageing populations, and increasing demand for affordable medicines.

The Indian pharmaceutical market is estimated at over USD 60 billion and is expected to grow steadily in the coming years. Globally, the pharmaceutical industry is valued at more than USD 1.5 trillion. Contract manufacturing, CRDMO, and CDMO segments are also witnessing strong growth because pharmaceutical companies are increasingly outsourcing manufacturing and research activities.

The industry is supported by technological developments such as AI-driven drug discovery, automation in sterile manufacturing, and digital quality systems. Demand for injectable manufacturing and formulation outsourcing is also increasing globally.

Major Indian pharmaceutical companies include Sun Pharma, Cipla, Dr. Reddy’s Laboratories, Lupin, and Aurobindo Pharma. Globally, companies such as Pfizer, Roche, Novartis, and Johnson & Johnson dominate the pharmaceutical sector.

The industry growth outlook remains positive because of strong export demand, increasing healthcare access, expansion of rural healthcare infrastructure, and higher demand for affordable generic medicines.

Major Risk Factors

1. Regulatory Compliance Risk

The pharmaceutical industry is highly regulated. Any failure to comply with GMP, CDSCO, FDA, or pollution control norms may lead to suspension of manufacturing operations, penalties, or cancellation of licenses, affecting revenue and business continuity.

2. Manufacturing Unit Suspension Risk

One of the company’s manufacturing units faced suspension of operations in 2023 due to regulatory non-compliance observations. Similar future actions by authorities may negatively impact production capacity, customer trust, and financial performance.

3. High Debt and Financial Leverage

The company had a high debt-to-equity ratio in earlier financial years. Although leverage improved in FY25 and IPO proceeds will partly reduce debt, future borrowings for expansion may increase financial pressure and interest obligations.

4. Dependency on Leased Properties

The company operates from leased industrial premises instead of owned properties. Any non-renewal of leases, rent escalation, or operational disruption at leased locations may affect manufacturing activities and increase operational costs.

5. Intense Industry Competition

The pharmaceutical formulations industry is highly competitive with strong competition from large established pharmaceutical companies. Competitive pricing pressure may impact profit margins, customer retention, and market share growth.

6. Regulatory Approval Delays for Expansion

The company’s proposed expansion project requires approvals from government authorities such as MPIDC and Nagar Nigam, Indore. Delays in receiving approvals may postpone expansion timelines and increase project execution costs.

7. Cash Flow and Working Capital Risk

The company reported negative operating cash flows during certain periods. Pharmaceutical businesses require significant working capital for inventory, receivables, and regulatory compliance, which may create pressure on liquidity and operations.

Key Strengths and Opportunities

1. Experienced Promoter Background

The promoters have more than 18 years of pharmaceutical industry experience across operations, sales, and business development. Their long industry exposure helps the company build client relationships, improve execution, and identify growth opportunities.

2. Diversified Product Portfolio

The company manufactures multiple pharmaceutical products such as injectables, tablets, syrups, capsules, ointments, and OTC products. Product diversification reduces dependence on a single therapy segment and supports wider market reach.

3. Expansion Opportunities in Contract Manufacturing

Global pharmaceutical companies are increasingly outsourcing manufacturing activities to reduce costs and improve efficiency. Bio Medica can benefit from increasing demand in CRDMO, CDMO, and third-party manufacturing services.

4. Growing Demand for Generic Medicines

India’s strong position in generic medicine exports and affordable healthcare products creates long-term demand opportunities for pharmaceutical manufacturers. Rising healthcare awareness and chronic diseases further support market growth.

5. Improving Financial Performance

The company’s EBITDA improved from ₹169.89 lakh in FY23 to ₹1,521.33 lakh in FY25, while PAT margins also improved significantly. Strong profitability improvement indicates better operational efficiency and scale benefits.

6. Strategic Expansion and Capacity Addition

The company is expanding manufacturing infrastructure in Indore to support future demand growth. Increased manufacturing capacity can improve economies of scale, product availability, and revenue generation potential.

7. Strong Industry Growth Outlook

The pharmaceutical sector continues to benefit from rising healthcare spending, export opportunities, digital healthcare adoption, and increasing outsourcing demand. Bio Medica is well-positioned to benefit from these long-term industry trends

Bio Medica Laboratories Limited is a pharmaceutical manufacturing company engaged in the production of formulations and healthcare products. The company earns revenue mainly through manufacturing and supplying pharmaceutical products, including injectables, tablets, capsules, dry syrups, ointments, and OTC products for domestic and export markets. Its products are used by hospitals, healthcare institutions, pharmacies, and pharmaceutical companies. The company also focuses on contract manufacturing and formulation development for third-party clients.

Key Clients and Manufacturing Facilities

The company operates manufacturing facilities at Sanwer Road Industrial Area, Indore, Madhya Pradesh. Manufacturing Unit-II is located at Plot No. 11-C, Sector-E, while Manufacturing Unit-I is situated at 254, Sector-F, Indore. These facilities support production of pharmaceutical formulations and healthcare products. The company also has infrastructure for future expansion at Plot No. 11B-11C. Bio Medica works with pharmaceutical distributors, institutional buyers, and healthcare companies across India.

Product Portfolio and Order Book Execution

Bio Medica’s product portfolio includes injectables, tablets, capsules, syrups, ointments, and OTC healthcare products. These products support different stages of the pharmaceutical product life cycle, from acute treatments to chronic therapies. The company also participates in contract manufacturing and formulation services, helping clients reduce production costs and improve speed-to-market. Execution of orders depends on manufacturing capacity, regulatory approvals, quality compliance, and timely raw material procurement.

Expansion Plans, Capex and Future Execution

The company is planning business expansion through the development of a new manufacturing facility at Plot No. 11B-11C, Sector-E, Sanwer Road, Indore. The company has already applied for approvals with MPIDC and Nagar Nigam, Indore. A portion of the IPO proceeds, including around ₹650 lakh, will be used for repayment of borrowings, strengthening the balance sheet, and supporting future capex plans. The expansion is expected to improve production capabilities and operational efficiency.

Employees and Banker to the Company

As of April 30, 2026, the company had 56 full time employees. The Banker to the Company is Kotak Mahindra Bank.

Management and Growth Vision

Bio Medica Laboratories is promoted by Pradeep Mehta and Mukesh Mehta, who together have more than 18-19 years of experience in the pharmaceutical industry. Pradeep Mehta, Managing Director, is responsible for growth strategy, innovation, and overall operations, while Mukesh Mehta handles marketing, business development, and sales operations.

The management is focused on expanding manufacturing capacity, improving product quality standards, and increasing its presence in domestic and export pharmaceutical markets. The company aims to strengthen its position in pharmaceutical formulations, contract manufacturing, and OTC healthcare products.

The long-term growth strategy includes setting up additional manufacturing infrastructure, increasing production automation, and expanding customer relationships with pharmaceutical companies. The management is also focusing on improving regulatory compliance and operational efficiency.

To fund future expansion and capex plans, the company plans to use IPO proceeds, internal accruals, and bank borrowings. Reduction of debt through IPO proceeds is expected to improve the company’s financial flexibility and support future growth opportunities.

Industry Overview

Bio Medica Laboratories operates in the Indian pharmaceutical formulations and contract manufacturing industry. India is one of the world’s largest suppliers of generic medicines and pharmaceutical products. The pharmaceutical sector benefits from increasing healthcare spending, rising chronic diseases, growing export opportunities, and government healthcare initiatives.

India is globally recognized as a major supplier of generic medicines and vaccines. The pharmaceutical industry is expected to continue growing due to rising domestic demand, ageing populations, and increasing demand for affordable medicines.

The Indian pharmaceutical market is estimated at over USD 60 billion and is expected to grow steadily in the coming years. Globally, the pharmaceutical industry is valued at more than USD 1.5 trillion. Contract manufacturing, CRDMO, and CDMO segments are also witnessing strong growth because pharmaceutical companies are increasingly outsourcing manufacturing and research activities.

The industry is supported by technological developments such as AI-driven drug discovery, automation in sterile manufacturing, and digital quality systems. Demand for injectable manufacturing and formulation outsourcing is also increasing globally.

Major Indian pharmaceutical companies include Sun Pharma, Cipla, Dr. Reddy’s Laboratories, Lupin, and Aurobindo Pharma. Globally, companies such as Pfizer, Roche, Novartis, and Johnson & Johnson dominate the pharmaceutical sector.

The industry growth outlook remains positive because of strong export demand, increasing healthcare access, expansion of rural healthcare infrastructure, and higher demand for affordable generic medicines.

Major Risk Factors

1. Regulatory Compliance Risk

The pharmaceutical industry is highly regulated. Any failure to comply with GMP, CDSCO, FDA, or pollution control norms may lead to suspension of manufacturing operations, penalties, or cancellation of licenses, affecting revenue and business continuity.

2. Manufacturing Unit Suspension Risk

One of the company’s manufacturing units faced suspension of operations in 2023 due to regulatory non-compliance observations. Similar future actions by authorities may negatively impact production capacity, customer trust, and financial performance.

3. High Debt and Financial Leverage

The company had a high debt-to-equity ratio in earlier financial years. Although leverage improved in FY25 and IPO proceeds will partly reduce debt, future borrowings for expansion may increase financial pressure and interest obligations.

4. Dependency on Leased Properties

The company operates from leased industrial premises instead of owned properties. Any non-renewal of leases, rent escalation, or operational disruption at leased locations may affect manufacturing activities and increase operational costs.

5. Intense Industry Competition

The pharmaceutical formulations industry is highly competitive with strong competition from large established pharmaceutical companies. Competitive pricing pressure may impact profit margins, customer retention, and market share growth.

6. Regulatory Approval Delays for Expansion

The company’s proposed expansion project requires approvals from government authorities such as MPIDC and Nagar Nigam, Indore. Delays in receiving approvals may postpone expansion timelines and increase project execution costs.

7. Cash Flow and Working Capital Risk

The company reported negative operating cash flows during certain periods. Pharmaceutical businesses require significant working capital for inventory, receivables, and regulatory compliance, which may create pressure on liquidity and operations.

Key Strengths and Opportunities

1. Experienced Promoter Background

The promoters have more than 18 years of pharmaceutical industry experience across operations, sales, and business development. Their long industry exposure helps the company build client relationships, improve execution, and identify growth opportunities.

2. Diversified Product Portfolio

The company manufactures multiple pharmaceutical products such as injectables, tablets, syrups, capsules, ointments, and OTC products. Product diversification reduces dependence on a single therapy segment and supports wider market reach.

3. Expansion Opportunities in Contract Manufacturing

Global pharmaceutical companies are increasingly outsourcing manufacturing activities to reduce costs and improve efficiency. Bio Medica can benefit from increasing demand in CRDMO, CDMO, and third-party manufacturing services.

4. Growing Demand for Generic Medicines

India’s strong position in generic medicine exports and affordable healthcare products creates long-term demand opportunities for pharmaceutical manufacturers. Rising healthcare awareness and chronic diseases further support market growth.

5. Improving Financial Performance

The company’s EBITDA improved from ₹169.89 lakh in FY23 to ₹1,521.33 lakh in FY25, while PAT margins also improved significantly. Strong profitability improvement indicates better operational efficiency and scale benefits.

6. Strategic Expansion and Capacity Addition

The company is expanding manufacturing infrastructure in Indore to support future demand growth. Increased manufacturing capacity can improve economies of scale, product availability, and revenue generation potential.

7. Strong Industry Growth Outlook

The pharmaceutical sector continues to benefit from rising healthcare spending, export opportunities, digital healthcare adoption, and increasing outsourcing demand. Bio Medica is well-positioned to benefit from these long-term industry trends